Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nepafenac

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 17,494Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE
    Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE

    23 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230123005117/en

    BUSINESSWIRE
    23 Jan 2023
    Share Share
    Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M
    Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

    15 Dec 2022

    // Zoey Becker FIERCEPHARMA

    https://www.fiercepharma.com/pharma/novartis-isnt-done-shaking-things-sells-five-eyecare-drugs-harrow-130-million

    Zoey Becker FIERCEPHARMA
    15 Dec 2022
    Share Share
    Imprimis NJOF, LLC Receives FDA Warning Letter
    Imprimis NJOF, LLC Receives FDA Warning Letter

    09 Jul 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/imprimis-njof-llc-receives-fda-warning-letter-1562735073.pdf

    FDA
    09 Jul 2019
    Share Share
    Mati Therapeutics PhII Nepafenac Evolute® Trial Results Show Significant Post
    Mati Therapeutics PhII Nepafenac Evolute® Trial Results Show Significant Post

    07 May 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190507005004/en/Mati-Therapeutics-Phase-II-Nepafenac-Evolute%C2%AE-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

    BUSINESSWIRE
    07 May 2019
    Share Share
    Mati Therapeutics PhII Results Signal Significant Post-op Pain Reduction
    Mati Therapeutics PhII Results Signal Significant Post-op Pain Reduction

    05 Sep 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180904005058/en/Mati-Therapeutics-Interim-Phase-II-Nepafenac-Clinical

    BUSINESSWIRE
    05 Sep 2018
    Share Share
    Prescription med: new or extended uses, new combinations of registered medicines
    Prescription med: new or extended uses, new combinations of registered medicines

    09 Jul 2018

    // TGA

    https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines

    TGA
    09 Jul 2018
    Share Share